Case report about fatal or near-fatal hypersensitivity reactions to cetuximab: Anticetuximab ige as a valuable screening test

Clinical Medicine Insights: Oncology

Volumn 8, Issue , 2014, Pages 91-94

  Dupont, Benoît ^a,b   Mariotte, Delphine ^a   Moldovan, Cristian ^c   Grellard, Jean Michel ^d   Vergnaud, Marie Claude ^a   Laroche, Dominique ^a,b   Gervais, Radj ^d  

^a CAEN UNIVERSITY HOSPITAL   (France)

^b UNIVERSITÉ DE CAEN   (France)

^c CENTRE HENRI BECQUEREL   (France)

^d CENTRE FRANÇOIS BACLESSE   (France)

Author keywords

Anaphylaxis; Antidrug IgE; Cetuximab; Hypersensitivity; Neoplasms

Indexed keywords

ADRENALIN; CETUXIMAB; CISPLATIN; DEXCHLORPHENIRAMINE; FLUOROURACIL; HISTAMINE; IMMUNOGLOBULIN E ANTIBODY; IPRATROPIUM BROMIDE; IRINOTECAN; METHYLPREDNISOLONE; TERBUTALINE; TRYPTASE;

ADULT; ADVANCED CANCER; AGED; ALLERGIC REACTION; ARTICLE; ARTIFICIAL VENTILATION; BRONCHOSPASM; CANCER COMBINATION CHEMOTHERAPY; CANCER RADIOTHERAPY; CANCER RECURRENCE; CARDIOPULMONARY INSUFFICIENCY; CASE REPORT; DRUG FATALITY; DRUG HYPERSENSITIVITY; DRUG MEGADOSE; DRUG WITHDRAWAL; DYSPNEA; ENZYME BLOOD LEVEL; FLUID RESUSCITATION; HEAD AND NECK CANCER; HIGH RISK PATIENT; HISTAMINE BLOOD LEVEL; HUMAN; HYPOTENSION; IMMUNOASSAY; IMMUNOGLOBULIN BLOOD LEVEL; INTRACUTANEOUS TEST; INTUBATION; MALAISE; MALE; MEDICAL HISTORY; METASTASIS; MIDDLE AGED; MOUTH CANCER; OXYGEN DESATURATION; OXYGEN THERAPY; PATIENT MONITORING; PREMEDICATION; RASH; RECTUM CANCER; RESPIRATORY ARREST; RISK ASSESSMENT; TACHYCARDIA; TACHYPNEA; UNCONSCIOUSNESS; VERY ELDERLY;

EID: 84905042961     PISSN: None     EISSN: 11795549     Source Type: Journal    
DOI: 10.4137/CMO.S13897     Document Type: Article

References (15)

1. Bonner JA, Harari PM, Giralt J, et al. Radiotherapy plus cetuximab for squamous-cell carcinoma of the head and neck. N Engl J Med. 2006;354(6):567-78.
2. Cunningham D, Humblet Y, Siena S, et al. Cetuximab monotherapy and cetuximab plus irinotecan in irinotecan-refractory metastatic colorectal cancer. N Engl J Med. 2004;351(4):337-45.
3. Hopps S, Medina P, Pant S, Webb R, Moorman M, Borders E. Cetuximab hypersensitivity infusion reactions: Incidence and risk factors. J Oncol Pharm Pract. 2013;19(3):222-7.
4. O'Neil BH, Allen R, Spigel DR, et al. High incidence of cetuximab-related infusion reactions in Tennessee and North Carolina and the association with atopic history. J Clin Oncol. 2007;25(24):3644-8.
5. Pirker R, Pereira JR, Szczesna A, et al. FLEX Study Team. Cetuximab plus chemotherapy in patients with advanced non-small-cell lung cancer (FLEX): an open-label randomised phase III trial. Lancet. 2009;373(9674):1525-31.
6. Vermorken JB, Mesia R, Rivera F, et al. Platinum-based chemotherapy plus cetuximab in head and neck cancer. N Engl J Med. 2008;359(11):1116-27.
7. Waqar SN, Tan BR, Zubal B, Kuperman DI, Adkins DR. Race and albuterol premedication are risk factors for hypersensitivity reactions to cetuximab. J Clin Oncol. 2008;26(suppl 15S): Abstract 9097.
8. Chung CH, Mirakhur B, Chan E, et al. Cetuximab-induced anaphylaxis and IgE specific for galactose-alpha-1,3-galactose. N Engl J Med. 2008;358(11):1109-17.
9. Mariotte D, Dupont B, Gervais R, et al. Anti-cetuximab IgE ELISA for identification of patients at a high risk of cetuximab-induced anaphylaxis. MAbs. 2011;3(4):396-401.
10. Patel DD, Goldberg RM. Cetuximab-associated infusion reactions: pathology and management. Oncology (Williston Park). 2006;20(11):1373-82; discussion 1382, 1392-84, 1397.
11. Hopps S, Medina P, Pant S, Webb R, Moorman M, Borders E. Cetuximab hypersensitivity infusion reactions: Incidence and risk factors. J Oncol Pharm Pract. 2013;19(3):222-7.
12. Grandvuillemin A, Disson-Dautriche A, Miremont-Salamé G, Fourrier-Reglat A, Sgro C. Réseau des Centres Régionaux de Pharmacovigilance Français. Cetuximab infusion reactions: French pharmacovigilance database analysis. J Oncol Pharm Pract. 2013;19(2):130-7.
13. Pointreau Y, Commins SP, Calais G, Watier H, Platts-Mills TA. Fatal infusion reactions to cetuximab: role of immunoglobulin e-mediated anaphylaxis. J Clin Oncol. 2012;30(3):334; author reply 335.
14. Tronconi MC, Sclafani F, Rimassa L, Carnaghi C, Personeni N, Santoro A. Fatal infusion reaction to cetuximab: the need for predictive risk factors and safer patient selection. J Clin Oncol. 2011;29(23):e680-1.
15. Ciccolini J, Gross E, Dahan L, Lacarelle B, Mercier C. Routine dihydropyrimidine dehydrogenase testing for anticipating 5-fluorouracil-related severe toxicities: hype or hope? Clin Colorectal Cancer. 2010;9(4):224-8.